I.

Pharmacists Workup of Drug Therapy for Bronchial asthma

Bronchial Asthma

PWDT Components FARM Notes

Findings Findings (F)
Subjective:
Difficulty of breathing
wheezes

Objective:
Determine suspected factors that
exacerbate asthma:
Allergens
Respiratory infections
Exercise and hyperventilation
Weather changes
Food,additives
Drugs

Desired Outcomes Assessments

Desired Endpoints
Drug-related problems
Therapeutic Selection
Maintain optimal breathing
pattern, as evidenced by relaxed
breathing, normal respiratory rate
Reduce exposure to some
categories of risk factors that
exacerbate asthma
Adherence to medication therapy
Improve quality of life
Resolution/ recommendation (R)
Encourage the patient to avoid
exposure to indoor allergens
Encourage the patient to engage
in some training on self
management skills
Should strictly adhere to drug
regimen.
Encourage the patient to take
note if their symptoms worsen or
their reliever use increase, so
they can implement their written
asthma action plan or get medical
care appropriate
 Regular medical review.

Monitoring Parameters Monitoring (m)

Follow-up Monitor potential factors that
exacerbate your asthma like
allergies.
Monitor patient medication intake

CORE Pharmacotherapy Plan

Condition: Bronchial Asthma in Acute exacerbation

Outcomes:

Maintain optimal breathing pattern, as evidenced by relaxed breathing, normal

respiratory rate
Reduce exposure to some categories of risk factors that exacerbate asthma
Adherence to medication therapy
Improve quality of life

Regimen:

Hydrocortisone 250mg
Salbutamol + ipratoprium
Salbutamol 2mg
Salbutamol 1mg + Guaifenesin 50mg per 5mL

Evaluation:

Ask patients about the presence and severity of symptoms and how symptoms
affect daily activities.
Evaluate the result of blood test that are specific for the allergen(s) suspected to
be causing symptoms, such as dust mites, mold, pet dander, and pollens; may
be ordered to help determine asthma triggers.
Evaluate patients compliance to the therapy.

PRIME Pharmacotherapy Problems

P=Pharmaceutical-based problems

Forgetfulness that leads to patients non-compliance.

R=Risk to Patient

Hydrocortisone 250mg
Sodium and fluid retention. Potassium and calcium depletion.
Salbutamol sulfate + ipratroprium bromide
 May cause paradoxical bronchospasm, fine tremor of skeletal muscle;
palpitations headache dizziness urinary retention

Salbutamol 2mg
May cause Tremor, nervousness, nausea and vomiting, tachycardia, palpitations, chest
pain, shakiness, dizziness, headache, insomnia, inhalation site sensation, , HTN,
hypotension, increased sweating, allergic reactions, DM, muscle cramps, flu-like
syndrome, conjunctivitis, UTI, hypokalaemia

Salbutamol 1mg + Guaifenesin50mg

Fine tremor of skeletal muscle, feeling of tension, peripheral vasodilation, compensatory
small increase in heart rate, headache and transient muscle cramps

I= Drug Interaction

none

M= Mismatch between medications and conditions of the patient needs

none

E= Efficacy Issues

Patients non-compliance.

II. Pharmacists Workup Drug Therapy for Hypertension

PWDT COMPONENTS FARM NOTES

Findings Findings (F)

Subjective
Difficulty of breathing
wheezing

Objective
Vital Signs
- Blood pressure rate
- Low pulse rate
- High respiratory rate

Desired Outcomes Assessments (A)

Desired End Point To manage and prevent the
Drug related problems symptoms of hypertension
Improve compliance with drug therapy
and lifestyle intervention
maintain a blood pressure to 130/80
Reduce cardiovascular morbidity and
 mortality
To improve quality of life
Therapeutic Selection Resolutions / Recommendations
Monitor blood pressure (monthly).
The medications that the patient is
taking must be properly monitored for
undesirable interactions. One may
have interaction to the other medicine
given.

CORE Phrmacotherapy Plan

Condition: Hypertension

Outcomes:

To manage and prevent the symptoms of hypertension

Improve compliance with drug therapy and lifestyle intervention
maintain a blood pressure to 130/80
Reduce cardiovascular morbidity and mortality
To improve quality of life

Regimen:

Captopril 25 mg

Evaluation:

Blood pressure should be monitored monthly and, once stabilized, it should be checked
every 6 to 12 months.
Ask patients about the presence and severity of symptoms and how symptoms affect
daily activities.
Evaluate patients compliance to the therapy.

PRIME Pharmacotherapy Problems

P = Pharmaceutical Based problem

 Forgetfulness that leads to patients non-compliance.

R = Risk to Patient

. Captopril
- Dehydration, excessive sweating, vomiting, or diarrhea may increase the risk of
low blood pressure.
I = Drug Interaction

No interaction

M = Mismatch between medications and conditions or patient needs

None

E = Efficacy Issues

Patients non-compliance.

III. Pharmacists Workup of Drug Therapy for Seizure

Seizure

PWDT Components FARM Notes

Findings Findings (F)
Subjective:

Objective:
Desired Outcomes Assessments
Desired Endpoints The goal of treatment in patients
Drug-related problems with seizure is to control the
seizure and achieve a seizure-
free status with the used of only
one drug, with the lowest possible
dose that causes the fewest side
effects possible.
Improve patients quality of life.
Therapeutic Selection Resolution/recommendation (R)
Monotherapy is desirable
because it decreases the
likelihood of adverse effects and
avoids drug interactions.
The choice of drugs should be
 made according to the seizure
type and previous treatment
history.
Drugs most suitable for the
patients seizure type should be
introduced slowly, starting with a
small dose which will be
increased incrementally to an
initial maintenance dose.
Monitoring Parameters Monitoring (M)
Follow-up Laboratory tests may be
performed while the patient is
under Levetiracetam medication
to monitor his condition and
check for possible side effects.
Monitor serum levels for
therapeutic range of medication.
Monitor patient for toxic adverse
effects of the medication.
Monitor platelet and liver
functions for toxicity due to
medication.
Assess compliance and
medication-taking strategies.

CORE Pharmacotherapy Plan

Condition: Seizure

Outcomes:

The goal of treatment in patients with seizure is to control the seizure and
achieve a seizure-free status with the used of only one drug, with the lowest
possible dose that causes the fewest side effects possible.
Improve patients quality of life.

Regimen: Levetiracetam 500 mg BID

Evaluation:

Evaluate patients compliance to the therapy.

Evaluate patients response to the therapy.
PRIME Pharmacotherapy Problems

P=Pharmaceutical-based problems

None

R=Risk to Patient

Levetiracetam may cause behavior changes and mental or mood problems.

Patients who take levetiracetam may also be at increased risk for suicidal
thoughts or actions. Other worsened or sudden symptoms such as depressed
mood, anxious, restless, or irritable behaviour, panic attacks, or any unusual
changes in mood or behavior may also occur.

I= Drug Interaction

none

M= Mismatch between medications and conditions of the patient needs

none

E= Efficacy Issues

None